Medications

Atezolizumab prolongs survival in NSCLC with PD-L1 expression

(HealthDay)—For patients with non-small cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) expression, treatment with atezolizumab results in longer overall survival than chemotherapy, according to a study ...

Oncology & Cancer

Immunotherapy offers hope for prostate cancer treatment

An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer. This is the finding of the long-term analyses of an international phase ...

Oncology & Cancer

Revealed: How cancer develops resistance to treatment

Cancer cells can turn on error-prone DNA copy pathways to adapt to cancer treatment, a breakthrough study published in the journal Science has revealed. Bacteria use the same process, termed stress-induced mutagenesis, to ...

Oncology & Cancer

Unique cells found in lung cancer patients may predict survival

Lung cancer is the leading cause of cancer-related deaths in the U.S. and most who are diagnosed with lung cancer do not survive five years. Non-small cell lung cancer (NSCLC) is the most common type where tumor cells shed ...

page 1 from 34